Tuberculosis (TB) is a major health problem of global proportions. In 2014, an estimated 9.6 million people fell ill with TB and 1.5 million people died, placing TB above HIV as the number one ...

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list ...

Please provide your email address to receive an email when new articles are posted on . Three all-oral 9-month treatments for drug-resistant tuberculosis were found to be noninferior to standard ...

"Time has stood still" for many who've been on complex regimens for decades ...

In the search for shorter, effective, and safe regimens to treat fluoroquinolone-susceptible, rifampin-resistant tuberculosis (TB), three 9-month regimens incorporating newer and repurposed drugs ...

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

Please provide your email address to receive an email when new articles are posted on . The ARTISTRY-1 and ARTISTRY-2 studies assessed a novel, single-tablet regimen. Both showed high efficacy and no ...

A study comparing one- and three-month antibiotic treatments to prevent active tuberculosis (TB) finds that a high percentage of patients successfully completed both regimens and suffered few adverse ...

This is an ASCO Meeting Abstract from the 2017 Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...